Genfit Q1 Revenue Falls to EUR 1.1 Million
May 15 (Reuters) -Genfit SA GNFT.PA:
REPORTED ON TUESDAY FIRST QUARTER 2024 FINANCIAL INFORMATION
REVENUES FOR FIRST THREE MONTHS OF 2024 AMOUNTED TO EUR 1.1 MILLION COMPARED TO EUR 5.0 MILLION FOR SAME PERIOD IN 2023
AS OF MARCH 31, 2024, CO’S CASH AND CASH EQUIVALENTS AMOUNTED TO EUR 74.0 MLN VERSUS EUR 128.6 MLN AS OF MARCH 31, 2023
EXPECTS ITS EXISTING CASH AND CASH EQUIVALENTS WILL ENABLE IT TO FUND OPERATING EXPENSES AND CAPITAL EXPENDITURE REQUIREMENTS UNTIL ABOUT Q4 2025
THIS ESTIMATION INCLUDES EXPECTATIONS TO RECEIVE FUTURE MILESTONE REVENUE IN 2024, SUBJECT TO APPROVAL BY APPLICABLE REGULATORY AUTHORITIES AND US AND EUROPEAN COMMERCIAL LAUNCHES OF ELAFIBRANOR IN PRIMARY BILIARY CHOLANGITIS (PBC) BY IPSEN IPN.PA, REPRESENTING ABOUT EUR 75.2 MLN
Source text for Eikon: ID:nGNE631xp9
Further company coverage: GNFT.PA
(Gdansk Newsroom)
</body></html>Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
